Back to Search
Start Over
Autologous hematopoietic stem cell transplantation with inadequate stem cell dose in patients with non-Hodgkin lymphoma.
- Source :
- Leukemia & Lymphoma; Feb2021, Vol. 62 Issue 2, p323-329, 7p
- Publication Year :
- 2021
-
Abstract
- Little is known regarding the outcome of lymphoma patients undergoing autologous hematopoietic stem cell transplantation (AHSCT) using inadequate hematopoietic stem cell (HSC) doses. Fifty-six patients were enrolled in the study, and the cohort was subdivided into two groups according to the infusion dose: < 1 × 10<superscript>6</superscript>/kg (poor HSC group) and 1–2 × 10<superscript>6</superscript>/kg (unfavorable HSC group). Compared with the unfavorable group, the poor HSC group had a longer median time to neutrophil (13 vs. 11 days, p =.007) and platelet engraftment (17 vs. 13 days, p =.024). CD34+ cell infusion dose of < 1 × 10<superscript>6</superscript>/kg was the only risk factor for neutrophil and platelet engraftment. The expected 3-year progression-free survival and overall survival rates for the whole cohort were 53% and 66%, and no statistical difference was observed between two groups. In conclusion, inadequate HSC infusion dose did not negatively impact AHSCT patient survival but significantly prolonged the time to hematopoietic engraftment. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 62
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 148515754
- Full Text :
- https://doi.org/10.1080/10428194.2020.1834092